Texas Instruments Incorporated

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 2,414 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Texas Instruments has a single class of common stock, one vote per share, quoted on The Nasdaq Global Select Market under ticker TXN (FY2025 10-K, Item 5). There is no dual-class structure and no founder-control block: the largest insider position, Executive Chairman Richard Templeton's 2.68 million shares, is 0.29 percent of the company with no enhanced voting rights.
• Texas Instruments does not file Form 13F under its own CIK 0000097476. Its complete EDGAR filing history (submissions JSON, checked 17 August 2026) contains no 13F-HR or 13F-NT of any vintage, consistent with it not acting as an institutional investment manager.
• Texas Instruments' holdings list is empty and that is the sourced finding, not a gap. The FY2025 Form 10-K (period ended 31 December 2025, filed 6 February 2026) and the Q2 FY2026 Form 10-Q (period ended 30 June 2026, filed 24 July 2026) were both searched in full for 'equity method', 'equity investment', 'non-marketable', 'measurement alternative', 'unrealized', 'strategic investment', 'joint venture', 'equity securities', 'affiliate', 'minority interest' and 'cost method'. The only equity-investment language found relates to (a) debt and equity holdings inside TI's mutual funds that back deferred-compensation liabilities and (b) equity securities held inside TI's U.S. and non-U.S. defined benefit pension plans. Both are investment-portfolio and benefit-plan assets managed for return and funding purposes, not strategic corporate stakes, and are excluded under the brief's money-market/treasury-holdings exclusion.
• Texas Instruments' growth and AI-manufacturing strategy is built on owned fabs (Sherman, Texas and Lehi, Utah, 300mm wafer facilities) and CHIPS Act incentives (up to $1.6 billion of direct federal funding plus a 35 percent investment tax credit on qualifying capex), not minority equity stakes in other companies. Searched the 10-K for 'CHIPS Act', 'U.S. government', 'warrant' and 'Department of Commerce': the CHIPS Act agreement is funding and tax-credit based, with no mention of the U.S. government receiving warrants or an equity stake in TI itself, unlike Intel's 2025 CHIPS Act equity deal. No U.S.-government register row is recorded as a result.
• Vanguard underwent an internal realignment effective 12 January 2026 (disclosed in Vanguard Group Inc.'s Schedule 13G/A filed 27 March 2026, accession 0000102909-26-002454): certain Vanguard subsidiaries and business divisions now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. under SEC Release No. 34-39538. That 13G/A confirms The Vanguard Group, Inc. itself now holds zero TI shares directly (0 sole/shared voting, 0 sole/shared dispositive). Consistent with this, Vanguard's own Form 13F filed for CIK 0000102909 for the quarters ended 31 March 2026 and 30 June 2026 are both 13F-NT (notice only, no holdings), so no post-realignment 13F-HR exists under that CIK. The last full 13F-HR under that CIK covers the quarter ended 31 December 2025 (96,527,471 shares) and predates the realignment, so it is not used here.
• The register's Vanguard row instead uses Vanguard Capital Management LLC (CIK 0002100119), one of the successor entities, which filed a fresh Schedule 13G on 30 April 2026 reporting 68,246,741 shares (7.49%) as of 31 March 2026. That filing's own text states it covers Vanguard Capital Management LLC plus Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers LLC and Vanguard Investments Australia Ltd, and explicitly excludes other Vanguard subsidiaries or affiliates whose ownership is disaggregated separately. This is therefore very likely an undercount of total Vanguard-family exposure to TI; see unknowns.
• All 30 June 2026 13F values are the managers' own reported market values at that date. BlackRock, State Street, Morgan Stanley and Geode's rows each imply a per-share price close to $298 on 30 June 2026, a consistent quarter-end mark; JPMorgan's implied price ($285) is somewhat lower, which may reflect a mix of valuation dates within its filing but was not investigated further given the time budget.
• Percentages are computed by this research against stated share counts, not taken from the 13F filings themselves (13F filings report shares and dollar value only, not percent of class). 913,247,686 shares outstanding as of 15 July 2026 (Q2 FY2026 10-Q cover page) is used for the four 30 June 2026 13F rows. 910,092,791 shares outstanding as of 15 April 2026 (Q1 FY2026 10-Q cover page) is used for the 31 March 2026 Vanguard Capital Management 13G row. 910,463,377 shares outstanding as of 23 February 2026 (the proxy's own voting record-date figure) is used for the insider rows measured as of 31 December 2025.
• The market capitalization of $255.33 billion is the figure published by stockanalysis.com as of 14 August 2026, alongside a $279.58 share price. Cross-check: 913,247,686 shares at $279.58 implies approximately $255.34 billion, consistent to within rounding.
• Insider rows overlap. The 'all executive officers and directors as a group' row of 5,477,727 shares (0.602 percent) contains the individually listed Templeton and Ilan rows above and must not be added to them.